Long-acting HIV prevention shot works better than daily pills in women
09 November 2020 - 19:44
An international HIV prevention trial comparing ViiV Healthcare’s long-acting cabotegravir injections to a daily regimen of Gilead Science’s Truvada pill in women has proved so successful that it has been stopped early, researchers announced on Monday.
The results offer hope of better HIV prevention for women, who bear the brunt of the HIV epidemic in sub-Saharan Africa...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.